Suppr超能文献

使用氟替卡滨 PET 成像在体内确定阿尔茨海默病的 Tau 亚型。

Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.

机构信息

Eli Lilly and Company, Indianapolis, IN, USA.

Avid Radiopharmaceuticals, Philadelphia, PA, USA.

出版信息

J Alzheimers Dis. 2019;71(3):1037-1048. doi: 10.3233/JAD-190264.

Abstract

At autopsy, individuals with Alzheimer's disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the relative number of tangle counts in these regions, have been proposed-hippocampal sparing (relative sparing of the hippocampus but high cortical load), limbic predominant (high hippocampal load but lower load in association cortices), and typical (balanced neurofibrillary tangles counts in the hippocampus and association cortices) AD-and shown to be associated with distinct antemortem clinical phenotypes. The ability to distinguish these AD subtypes from the more typical tau signature in vivo could have important implications for clinical research. Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50-92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied. By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo. 6/45 (13%) participants were identified as hippocampal sparing and 6/45 (13%) as limbic predominant AD subtypes. Hippocampal sparing participants were significantly younger than those assigned to the other two subtypes. Worse performance on delayed recall was associated with increased hippocampal tau signal, and worse performance on the trail making test B-A was associated with lower values of the hippocampus to cortex ratio. Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes.

摘要

在尸检中,阿尔茨海默病(AD)患者的神经纤维缠结在新皮质和海马区的分布存在异质性。使用基于这些区域中缠结计数相对数量的算法定义了 AD 的亚型-海马保留(海马相对保留,但皮质负荷高)、边缘优势(海马负荷高,但联合皮质负荷低)和典型(海马和联合皮质中的神经纤维缠结计数平衡)AD-并显示与独特的生前临床表型相关。能够将这些 AD 亚型与更典型的 tau 特征在体内区分开来,可能对临床研究具有重要意义。对 45 名淀粉样蛋白阳性参与者的氟脱氧葡萄糖正电子发射断层扫描(PET)图像进行了研究,这些参与者在临床上被定义为轻度认知障碍或 AD,年龄在 50-92 岁之间,56%为女性,根据他们的 tau 病理 PET 模式,估计处于 Braak V-VI 阶段。通过将神经病理学算法转换为氟脱氧葡萄糖 PET 扫描,体内识别出与尸检结果一致且具有相似患病率的 tau 病理模式。45 名参与者中有 6 名(13%)被确定为海马保留型 AD,6 名(13%)为边缘优势型 AD。海马保留型参与者明显比其他两种亚型的参与者年轻。延迟回忆表现较差与海马 tau 信号增加有关,而追踪测试 B-A 表现较差与海马与皮质比值较低有关。前瞻性研究可以进一步验证氟脱氧葡萄糖 SUVR 截止值和相应 AD 亚型的表型。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验